Baicalein Protects against Type 2 Diabetes via Promoting Islet β-Cell Function in Obese Diabetic Mice. 2014

Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
Department of Human Nutrition, Foods & Exercises, College of Agriculture and Life Sciences, Virginia Tech, 1981 Kraft Drive, Corporate Research Center, Blacksburg, VA 24061, USA.

In both type 1 (T1D) and type 2 diabetes (T2D), the deterioration of glycemic control over time is primarily caused by an inadequate mass and progressive dysfunction of β-cell, leading to the impaired insulin secretion. Here, we show that dietary supplementation of baicalein, a flavone isolated from the roots of Chinese herb Scutellaria baicalensis, improved glucose tolerance and enhanced glucose-stimulated insulin secretion (GSIS) in high-fat diet (HFD-) induced middle-aged obese mice. Baicalein had no effect on food intake, body weight gain, circulating lipid profile, and insulin sensitivity in obese mice. Using another mouse model of type 2 diabetes generated by high-fat diet (HFD) feeding and low doses of streptozotocin injection, we found that baicalein treatment significantly improved hyperglycemia, glucose tolerance, and blood insulin levels in these middle-aged obese diabetic mice, which are associated with the improved islet β-cell survival and mass. In the in vitro studies, baicalein significantly augmented GSIS and promoted viability of insulin-secreting cells and human islets cultured either in the basal medium or under chronic hyperlipidemic condition. These results demonstrate that baicalein may be a naturally occurring antidiabetic agent by directly modulating pancreatic β-cell function.

UI MeSH Term Description Entries

Related Publications

Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
January 2016, Food science and biotechnology,
Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
January 2023, Journal of ethnopharmacology,
Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
January 2022, Diabetes, metabolic syndrome and obesity : targets and therapy,
Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
July 2017, Diabetes,
Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
June 2013, Autoimmunity,
Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
February 2016, Immunology and cell biology,
Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
September 2015, Molecular medicine reports,
Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
March 2013, Pediatric diabetes,
Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
October 2014, Metabolism: clinical and experimental,
Yu Fu, and Jing Luo, and Zhenquan Jia, and Wei Zhen, and Kequan Zhou, and Elizabeth Gilbert, and Dongmin Liu
January 2022, Handbook of experimental pharmacology,
Copied contents to your clipboard!